Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement
about
Interventions for renal vasculitis in adultsRecent advances in anti-neutrophil cytoplasmic antibody-associated vasculitisSpotlight on rituximab in the treatment of antineutrophil cytoplasmic antibody-associated vasculitis: current perspectivesWhat is new in the management of rapidly progressive glomerulonephritis?Patient-Reported Outcomes in Glomerular Disease.Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue.Pro: Should all patients with anti-neutrophil cytoplasmic antibody-associated vasculitis be primarily treated with rituximab?Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type.Rituximab therapy for IgA-vasculitis with nephritis: a case series and review of the literature.Clinical trials in antineutrophil cytoplasmic antibody-associated vasculitis: what we have learnt so far, and what we still have to learn.Con: Should all patients with anti-neutrophil cytoplasmic antibody-associated vasculitis be primarily treated with rituximab?Moderator's view: Should all patients with ANCA-associated vasculitis be primarily treated with rituximab?Complement C5-inhibiting therapy for the thrombotic microangiopathies: accumulating evidence, but not a panacea.Understanding the role of rituximab in ANCA GN: regressing toward the meanSystematic review of the role of rituximab in treatment of antineutrophil cytoplasmic autoantibody-associated vasculitis, hepatitis C virus-related cryoglobulinemic vasculitis, Henoch-Schönlein purpura, ankylosing spondylitis, and Raynaud's phenomenInterstitial Immunostaining and Renal Outcomes in Antineutrophil Cytoplasmic Antibody-Associated Glomerulonephritis.An Elderly Man with Fatigue, Dyspnea, and Kidney Failure.End-stage renal disease in ANCA-associated vasculitis.Antineutrophil cytoplasmic antibody associated vasculitides with renal involvement: Open challenges in the remission induction therapy.Case Report: Patient with Hepatitis C, p-ANCA, and Cryoglobulin Antibodies Presenting with Necrotizing Crescentic p-ANCA GlomerulonephritisPediatric Nephrology and Rheumatology Practice Patterns in Granulomatosis with Polyangiitis: A Midwest Pediatric Nephrology Consortium Study
P2860
Q24187038-834FB199-76C7-435E-9DBB-236D86C77758Q26751357-32AC9ACE-5939-4A6B-BD0B-C2430D2C0E36Q26776308-90CFAEA2-50CA-4EC1-BD96-C2C9096F979DQ28259540-F8315182-974A-4CC4-9D36-13B97FC08D8AQ30249861-02B21A05-BBA4-4990-8F7E-177F213F1DB6Q30276550-5ABC4D06-9B70-4D91-9A74-891DCC9E963FQ35777619-24E595F3-FC06-4749-9B04-EEE9AE4FA71CQ37006816-AD9AE5F0-DE18-4643-8D7C-351B7A9AB190Q38905969-AA68AB8B-AB87-4FF4-AA3F-C155D65E4628Q39088103-86A70497-E1C0-4946-8A71-2744EE5DC582Q41208157-AE8BEEED-E47C-48AA-A458-6AC19F428FB8Q41208166-6EEBCCD9-4A8B-4CCB-87D0-D06258773934Q42086661-F4005521-195F-403D-9B55-6BD27CD3B471Q42563782-D669CD8F-EE69-4832-B308-50D3FC477BB0Q47163408-C5D997FA-7A97-4F81-9006-96F564DFEDB0Q50206075-6AD0CD7F-B167-46F3-8017-95B9AAFFF6B2Q53452166-AE3B5737-A9D2-4A34-8BD8-87CF6FA77265Q53513595-2C550B5F-062B-4AB0-B9AC-4EC0C70DC3A6Q55340553-E45A37D9-F507-4462-94DC-F14F246D09F0Q58789402-487E78E7-E88E-4C38-AB2D-B8588ACC16DCQ58800147-E46A605D-7EFF-4554-BB17-B021499EDF89
P2860
Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement
description
2014 nî lūn-bûn
@nan
2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement
@ast
Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement
@en
type
label
Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement
@ast
Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement
@en
prefLabel
Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement
@ast
Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement
@en
P2093
P2860
P356
P1476
Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement
@en
P2093
Barri J Fessler
Brett Jepson
Carol A Langford
David Ikle
Duvuru Geetha
E William St Clair
Fernando C Fervenza
Gary S Hoffman
John H Stone
Linna Ding
P2860
P304
P356
10.1681/ASN.2014010046
P577
2014-11-07T00:00:00Z